Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a global consumer-health company listed on the LSE and NYSE, filed this Form 6-K for May 2024. The filing was dated May 1, 2024, and reports a change to the company’s Board and Audit & Risk Committee leadership.
Haleon’s principal categories include oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements. Key brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
Financial and operating metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
- Deirdre Mahlan is stepping down as Haleon’s Non-Executive Director and Chair of the Audit & Risk Committee following her appointment as President, Chief Executive Officer, and Chairperson of The Duckhorn Portfolio, Inc.
- Mahlan will continue in her Haleon roles until a successor is identified.
- Haleon has begun a search for her successor. The filing does not identify a successor or provide a timetable for the appointment.
Guidance, outlook, risks, and unusual items
The filing contains no financial guidance or operating outlook. The principal reported matter is the pending transition of the Audit & Risk Committee chair. The overlapping role period is an unusual governance arrangement that will continue until a successor is appointed.
Key facts for investors to verify
- The timing and identity of Deirdre Mahlan’s successor.
- Whether the Board or Audit & Risk Committee announces any additional changes to composition or responsibilities.
- Any subsequent disclosure regarding the impact of the transition on Haleon’s governance, reporting, or financial outlook.